FindTrial
Sign In

A diagnostic platform based on microfluidic technology to study chemotherapy and radiation therapy sensitivity in breast cancer patients.

Cancer-on-Chip: Developing a state-of-the-art microfluidic diagnostic Organ-on-Chip (OoC) platform to study ex vivo chemo radiation sensitivity in breast cancer patients. - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/03/063626
Enrollment
104
Registered
2024-03-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C506- Malignant neoplasm of axillary tail of breast Health Condition 2: C509- Malignant neoplasm of breast of unspecified site Health Condition 3: C501- Malignant neoplasm of central portion of breast Health Condition 4: C503- Malignant neoplasm of lower-innerquadrant of breast Health Condition 5: C505- Malignant neoplasm of lower-outerquadrant of breast Health Condition 6: C500- Malignant neoplasm of nipple and areola Health Condition 7: C508- Malignant neoplasm of overlappi

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Sanjiban Chakrabarty
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: We will prospectively recruit breast cancer patients with clinically confirmed malignant disease in our study for four-year study period. Patient receiving carboplatin for neoadjuvant chemotherapy will be included.

Exclusion criteria

Exclusion criteria: 1) Age above 70 years, 2)Medically compromised, 3)Low-performance status. Patients with pulmonary and/or bone metastasis will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Development of cancer-on-chip platform based on microfluidic to measure drug response and radiation response in breast cancer patients.Timepoint: Development of cancer-on-chip platform based on microfluidic to measure drug response and radiation response in breast cancer patients: 4 years—

Secondary

MeasureTime frame
Understanding of the resistance mechanism of carboplatin resistance using patient derived 3D models. Identification of new vulnerabilities to target drug resistance TNBC.Timepoint: Understanding of the resistance mechanism of carboplatin resistance using patient derived 3D model: 2 years Identification of new vulnerabilities to target drug resistance TNBC: 4 years—

Countries

India

Contacts

Public ContactDr Sanjiban Chakrabarty

Manipal School of Life Sciences

sanjiban.c@manipal.edu9986297508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026